Cargando…

Dravet syndrome

"Dravet syndrome" (DS) previously named severe myoclonic epilepsy of infancy (SMEI), or epilepsy with polymorphic seizures, is a rare disorder characterized by an early, severe, generalized, epileptic encephalopathy. DS is characterized by febrile and afebrile seizures beginning in the 1st...

Descripción completa

Detalles Bibliográficos
Autor principal: Incorpora, Gemma
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745418/
https://www.ncbi.nlm.nih.gov/pubmed/19737414
http://dx.doi.org/10.1186/1824-7288-35-27
_version_ 1782171963612987392
author Incorpora, Gemma
author_facet Incorpora, Gemma
author_sort Incorpora, Gemma
collection PubMed
description "Dravet syndrome" (DS) previously named severe myoclonic epilepsy of infancy (SMEI), or epilepsy with polymorphic seizures, is a rare disorder characterized by an early, severe, generalized, epileptic encephalopathy. DS is characterized by febrile and afebrile seizures beginning in the 1st year of life followed by different types of seizures (either focal or generalized), which are typically resistant to antiepileptic drugs. A developmental delay from the 2nd to 3rd year of life becomes evident, together with motor disturbances and personality disorders. Beside the classic syndrome, there are milder cases which have been called severe myoclonic epilepsy borderline (SMEB). DS is caused by a mutation in the neuronal sodium channel gene, SCN1A , that is also mutated in generalized epilepsy with FS+ (GEFS+).
format Text
id pubmed-2745418
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27454182009-09-17 Dravet syndrome Incorpora, Gemma Ital J Pediatr Review "Dravet syndrome" (DS) previously named severe myoclonic epilepsy of infancy (SMEI), or epilepsy with polymorphic seizures, is a rare disorder characterized by an early, severe, generalized, epileptic encephalopathy. DS is characterized by febrile and afebrile seizures beginning in the 1st year of life followed by different types of seizures (either focal or generalized), which are typically resistant to antiepileptic drugs. A developmental delay from the 2nd to 3rd year of life becomes evident, together with motor disturbances and personality disorders. Beside the classic syndrome, there are milder cases which have been called severe myoclonic epilepsy borderline (SMEB). DS is caused by a mutation in the neuronal sodium channel gene, SCN1A , that is also mutated in generalized epilepsy with FS+ (GEFS+). BioMed Central 2009-09-08 /pmc/articles/PMC2745418/ /pubmed/19737414 http://dx.doi.org/10.1186/1824-7288-35-27 Text en Copyright © 2009 Incorpora; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Incorpora, Gemma
Dravet syndrome
title Dravet syndrome
title_full Dravet syndrome
title_fullStr Dravet syndrome
title_full_unstemmed Dravet syndrome
title_short Dravet syndrome
title_sort dravet syndrome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745418/
https://www.ncbi.nlm.nih.gov/pubmed/19737414
http://dx.doi.org/10.1186/1824-7288-35-27
work_keys_str_mv AT incorporagemma dravetsyndrome